Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
Many studies have confirmed that the human poliovirus receptor (PVR; CD155) is related to tumor cell migration, invasion, and thus tumor progression. A PVR receptor binds its ligand T cell Ig and the ITIM domain (TIGIT) to inhibit the function of T and NK cells, thereby allowing tumors to evade immu...
Saved in:
Main Authors: | Yu-Hang Duan (Author), Yan-lin Bian (Author), Jian-Wei Zhu (Author) |
---|---|
Format: | Book |
Published: |
Georg Thieme Verlag KG,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024) -
Structural and functional characterization of a monoclonal antibody blocking TIGIT
by: Bo-Seong Jeong, et al.
Published: (2022) -
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
by: Jinah Yeo, et al.
Published: (2021) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
by: Li SY, et al.
Published: (2013) -
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024)